Berkeley Lights, Inc. announced the Opto™ Plasma B Discovery 4.0 workflow. Opto Plasma B Discovery 4.0 is the industry’s premier antibody discovery workflow by advancing from B cells to lead molecules in just 1 week. This workflow enables customers to: Sample 4x more of the relevant biodiversity, screening up to 100,000 cells. Functionally test with highly sensitive cell-based assays. Recover not only sequences, but also re-expressed molecules without requiring costly gene synthesis and bacterial cloning. Increase the probability of success against hard-to-hit targets such as GPCRs and Ion Channels. By leveraging proprietary OptoSeq™ Barcoded BCR, enable rapid, accurate sequencing of paired heavy/light chain antibody genes by DNA fragmentation, NGS sequencing, and bioinformatics analysis. Additionally, Opto BCR Rapid Re-expression can be leveraged to rapidly re-express over one thousand antibodies in just one week to confirm their function in plate-based assays, reducing the cost and labor associated with gene synthesis and bacterial cloning.